- Home
- CIM vs PHVS Comparison
CIM vs PHVS Comparison
Compare CIM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- PHVS
- Stock Information
- Founded
- CIM 2007
- PHVS 2015
- Country
- CIM United States
- PHVS Switzerland
- Employees
- CIM N/A
- PHVS N/A
- Industry
- CIM Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- PHVS Health Care
- Exchange
- CIM Nasdaq
- PHVS Nasdaq
- Market Cap
- CIM 1.1B
- PHVS 1.3B
- IPO Year
- CIM 2007
- PHVS 2021
- Fundamental
- Price
- CIM $14.23
- PHVS $23.35
- Analyst Decision
- CIM Buy
- PHVS Strong Buy
- Analyst Count
- CIM 3
- PHVS 5
- Target Price
- CIM $15.50
- PHVS $35.60
- AVG Volume (30 Days)
- CIM 462.6K
- PHVS 130.6K
- Earning Date
- CIM 11-05-2025
- PHVS 08-12-2025
- Dividend Yield
- CIM 10.26%
- PHVS N/A
- EPS Growth
- CIM N/A
- PHVS N/A
- EPS
- CIM 1.28
- PHVS N/A
- Revenue
- CIM $312,281,000.00
- PHVS N/A
- Revenue This Year
- CIM $15.99
- PHVS N/A
- Revenue Next Year
- CIM $9.70
- PHVS N/A
- P/E Ratio
- CIM $11.23
- PHVS N/A
- Revenue Growth
- CIM 1.91
- PHVS N/A
- 52 Week Low
- CIM $9.85
- PHVS $11.51
- 52 Week High
- CIM $16.89
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- CIM 53.05
- PHVS 55.15
- Support Level
- CIM $13.83
- PHVS $21.50
- Resistance Level
- CIM $14.62
- PHVS $24.83
- Average True Range (ATR)
- CIM 0.23
- PHVS 1.43
- MACD
- CIM 0.02
- PHVS -0.01
- Stochastic Oscillator
- CIM 39.05
- PHVS 55.52
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.